<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="Research Article" dtd-version="1.0"><front><journal-meta><journal-id journal-id-type="pmc">iarjacc</journal-id><journal-id journal-id-type="pubmed">IARJACC</journal-id><journal-id journal-id-type="publisher">IARJACC</journal-id><issn>2709-1880</issn></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/iarjacc.2022.v03i02.71</article-id><title-group><article-title>Institutionalized Mitochondrial Disorders Are at Risk of Dying from Unrecognized Sars-Cov-2 Infection</article-title></title-group><abstract>A limitation of the study is that a SARS-CoV-2 infection was not ruled out as the cause of gastro-enteritis leading to the initial admission. Because the events apparently took place after the start of the SARS-CoV-2 pandemic, it cannot be ruled out that the patient deteriorated because of an undiagnosed COVID-19 infection. Arguments for a SARS-CoV-2 infection are that the patient was institutionalized and manifested with gastro-enteritis. Institutionalized patients are at an increased risk of contracting and dying from a SARS-CoV-2 infection [2]. It is also known that SARS-CoV-2 infections can manifest itself not only in the lungs but also in extra-pulmonary sites, including the gastro-intestinal tract [3]. In patients with manifestations of COVID-19 with extra-pulmonary onset, the causative agent can be difficult to confirm. We should be told whether the patient was SARS-CoV-2 vaccinated at the time of the first deterioration.&amp;nbsp;</abstract></article-meta></front><body /><back /></article>